NVO 6-K
Novo Nordisk A S (NVO)
6-K
2026-08-10
For: 2026-08-06
View Original
Added on
August 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 6, 2026
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
|---|
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | DÉSIRÈE JANTZEN ASGREEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Member of the Board of Directors | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | ELISABETH DAHL CHRISTENSEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Member of the Board of Directors | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | METTE BØJER JENSEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Member of the Board of Directors | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | SEMSI KILIC MADSEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Member of the Board of Directors | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | EMIL KONGSHØJ LARSEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, International<br>Operations | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme<br>– Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | KARSTEN MUNK KNUDSEN | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, Chief Financial<br>Officer (CFO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | KASPER BØDKER MEJLVANG | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, Global Manufacturing<br>& Supply | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | MAZIAR MIKE DOUSTDAR | ||
| 2 | Reason for the notification | |||
| a) | Position/status | President and CEO | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme<br>– Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | MARTIN HOLST LANGE | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, R&D and Chief<br>Scientific Officer (CSO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | THILDE GYNTHE BØGEBJERG KRØYER | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, Enterprise IT &<br>Quality | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name of the Board<br><br> <br>member/Executive/Associated Person | TANIA SABROE | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, People,<br>Organisation & Corporate Affairs | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance<br>with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 74 | |||
| d) | Aggregated information<br><br> <br>· Aggregated volume<br><br> <br>· Price | 74 shares<br><br> <br>DKK 21,778.20 | ||
| e) | Date of the transaction | 2026-08-05 | ||
| f) | Place of the transaction | Outside a trading venue |
Novo Nordisk is a leading global healthcarecompany founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon ourheritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimatelycure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk'sB shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visitnovonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | **** |
|---|---|
| Ambre James-Brown<br><br> <br>+45 3079 9289<br><br> <br>[email protected] | Liz Skrbkova**(US)**<br><br> <br>+1 609 917 0632<br><br> <br>[email protected] |
| Investors: | **** |
| Michael Novod<br><br> <br>+45 3075 6050<br><br> <br>[email protected] | Sina Meyer<br><br> <br>+45 3079 6656<br><br> <br>[email protected] |
| Alex Bruce<br><br> <br>+45 3444 2613<br><br> <br>[email protected] | Mads Berner Bruun<br><br> <br>+45 3075 2936<br><br> <br>[email protected] |
| Christoffer Togo Solgaard-Tullin<br><br> <br>+45 3079 1471<br><br> <br>[email protected] | Ida Schaap Melvold<br><br> <br>+45 3077 5649<br><br> <br>[email protected] |
| Frederik Taylor Pitter (US)<br><br> <br>+1 609 613 0568<br><br> <br>[email protected] |
| Novo Nordisk A/S<br><br>Investor Relations | Novo Alle 1<br><br>2880 Bagsværd<br><br>Denmark | Telephone:<br><br>+45 4444 8888 | www.novonordisk.com<br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company<br> announcement No 49 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 6, 2026 | NOVO NORDISK A/S<br><br> <br><br><br> <br>Maziar Mike Doustdar<br><br> <br>Chief Executive Officer |
|---|